Abstract
Background: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion.
Case Description: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus.
Conclusion: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
Keywords: Pruritus, canagliflozin, adverse drug reaction, SGLT2, pharmacology, sodium-glucose.
Graphical Abstract
Current Drug Safety
Title:Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
Volume: 13 Issue: 1
Author(s): Piero Vasapollo, Erika Cione, Filippo Luciani and Luca Gallelli*
Affiliation:
- Department of Health Science, University of Catanzaro and Operative Unit of Clinical Pharmacology and Pharmacovigilance, Mater Domini Hospital, Catanzaro,Italy
Keywords: Pruritus, canagliflozin, adverse drug reaction, SGLT2, pharmacology, sodium-glucose.
Abstract: Background: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion.
Case Description: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus.
Conclusion: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
Export Options
About this article
Cite this article as:
Vasapollo Piero, Cione Erika, Luciani Filippo and Gallelli Luca*, Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886311666160405110515
DOI https://dx.doi.org/10.2174/1574886311666160405110515 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Oxygen Radicals on Bronchial Asthma
Current Drug Targets - Inflammation & Allergy Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Evaluation of the Antidiabetic Property of Capparis Ovata Desf. Var. Palaestina Zoh. Extracts Using In vivo and In vitro Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Editorial [Hot topic: Sepsis Pathogenesis: How Many Pieces are There in the Puzzle? (Guest Editor: Luciano Cesar Pontes Azevedo)]
Endocrine, Metabolic & Immune Disorders - Drug Targets The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science Quantification of Specific Glycation Sites in Human Serum Albumin as Prospective Type 2 Diabetes Mellitus Biomarkers
Protein & Peptide Letters Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus
Current Vascular Pharmacology Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Adrenergic Regulation of Macrophage-Mediated Innate/Inflammatory Responses in Obesity and Exercise in this Condition: Role of β2 Adrenergic Receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Insulin Resistance and Polycystic Ovary Syndrome
Current Pharmaceutical Design